WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

David T. Rubin  ¹     Irene Modesto  ²     Severine Vermeire  ³     Silvio Danese  ⁴     Siew C. Ng  ⁵     Nana Koram  ⁶     Kenneth Kwok  ⁶     Thomas V Jones  ^7    
1 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
² Pfizer Inc, New Yor, United States
³ University Hospitals Leuven, Leuven, Belgium
⁴ Humanitas University, Milan, Italy
⁵ LKS Institute of Health Science, Chinese University of Hong Kong, Institute of Digestive Disease, Hong Kong, Hong Kong
⁶ Pfizer Inc, New York, United States
⁷ Pfizer Inc, Collegeville, United States

Topic
IBD

Session
Safety and outcomes of interventions in IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)